Role of the International Society of Liquid Biopsy (ISLB) in establishing quality control frameworks for clinical integration


Por: N. FUSCO, E. JANTUS-LEWINTRE, M. SERRANO, D. GANDARA, U. MALAPELLE and C. ROLFO

Publicada: 1 may 2025 Ahead of Print: 1 abr 2025
Resumen:
Liquid biopsy (LB) has revolutionized molecular pathology, offering non-invasive insights into tumor biology. However, its wide adoption is hindered by a lack of standardized protocols, requiring robust quality control frameworks and harmonized diagnostic workflows. Large consensensus initiatives are needed to establish effective standard operating procedures (SOPs), particularly for circulating tumor DNA (ctDNA) testing, tailored to different disease types and stages. The International Society of Liquid Biopsy (ISLB) has addressed these challenges by forming a Quality Control and Accreditation Committee, focused on developing frameworks for pre-analytical, analytical, and interpretive processes. Key priorities include mitigating pre-analytical variability with stringent guidelines for blood handling and ensuring adherence to international standards like ISO 15189 and CLIA/CAP. ISLB emphasizes the need for harmonized methodologiesand diagnostic workflows for molecular testing. Collaboration with global initiatives, including the European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), and International Liquid Biopsy Standardization Alliance (ILSA) are vital for integrating LB into clinical care, advancing precision oncology, and improving patient outcomes .

Filiaciones:
N. FUSCO:
 European Inst Oncol IRCCS, Div Pathol, Milan, Italy

 Univ Milan, Dept Oncol & Hemato Oncol, Milan, Italy

:
 Univ Politecn Valencia, Dept Biotechnol, Unidad Mixta TRIAL, Fdn Invest Hosp Gen Univ Valencia, Valencia, Spain

 Ctr Invest Principe Felipe, Valencia, Spain

 CIBERONC, Valencia, Spain

M. SERRANO:
 Univ Granada, Ctr Genom & Oncol Res, Liquid Biopsy & Canc Intercept Grp, GENyO,Pfizer,Andalusian Reg Govt,PTS Granada,Patho, Ave Ilustrac 114, Granada 18016, Spain

D. GANDARA:
 Univ Calif Davis, Dept Med, Div Hematol & Oncol, Comprehens Canc Ctr, Sacramento, CA 95817 USA

U. MALAPELLE:
 Univ Naples Federico II, Dept Publ Hlth, Naples, Italy

C. ROLFO:
 Arthur G James Canc Hosp, Div Radiat Oncol, Columbus, OH USA
ISSN: 10408428





CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Editorial
ELSEVIER SCIENCE INC, STE 800, 230 PARK AVE, NEW YORK, NY 10169, Estados Unidos America
Tipo de documento: Letter
Volumen: 209 Número:
Páginas:
WOS Id: 001473933900001
ID de PubMed: 39824370

MÉTRICAS